SG11202106678PA - Method and systems for prediction of hla class ii-specific epitopes and characterization of cd4+ t cells - Google Patents
Method and systems for prediction of hla class ii-specific epitopes and characterization of cd4+ t cellsInfo
- Publication number
- SG11202106678PA SG11202106678PA SG11202106678PA SG11202106678PA SG11202106678PA SG 11202106678P A SG11202106678P A SG 11202106678PA SG 11202106678P A SG11202106678P A SG 11202106678PA SG 11202106678P A SG11202106678P A SG 11202106678PA SG 11202106678P A SG11202106678P A SG 11202106678PA
- Authority
- SG
- Singapore
- Prior art keywords
- characterization
- prediction
- cells
- systems
- hla class
- Prior art date
Links
- 210000001744 T-lymphocyte Anatomy 0.000 title 1
- 238000012512 characterization method Methods 0.000 title 1
- 238000000034 method Methods 0.000 title 1
Classifications
-
- G—PHYSICS
- G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
- G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
- G16B30/00—ICT specially adapted for sequence analysis involving nucleotides or amino acids
-
- G—PHYSICS
- G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
- G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
- G16B15/00—ICT specially adapted for analysing two-dimensional or three-dimensional molecular structures, e.g. structural or functional relations or structure alignment
- G16B15/30—Drug targeting using structural data; Docking or binding prediction
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70503—Immunoglobulin superfamily
- C07K14/70539—MHC-molecules, e.g. HLA-molecules
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2833—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against MHC-molecules, e.g. HLA-molecules
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
-
- G—PHYSICS
- G06—COMPUTING; CALCULATING OR COUNTING
- G06N—COMPUTING ARRANGEMENTS BASED ON SPECIFIC COMPUTATIONAL MODELS
- G06N3/00—Computing arrangements based on biological models
- G06N3/02—Neural networks
- G06N3/04—Architecture, e.g. interconnection topology
- G06N3/0464—Convolutional networks [CNN, ConvNet]
-
- G—PHYSICS
- G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
- G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
- G16B20/00—ICT specially adapted for functional genomics or proteomics, e.g. genotype-phenotype associations
- G16B20/30—Detection of binding sites or motifs
-
- G—PHYSICS
- G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
- G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
- G16B25/00—ICT specially adapted for hybridisation; ICT specially adapted for gene or protein expression
- G16B25/10—Gene or protein expression profiling; Expression-ratio estimation or normalisation
-
- G—PHYSICS
- G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
- G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
- G16B30/00—ICT specially adapted for sequence analysis involving nucleotides or amino acids
- G16B30/10—Sequence alignment; Homology search
-
- G—PHYSICS
- G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
- G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
- G16B40/00—ICT specially adapted for biostatistics; ICT specially adapted for bioinformatics-related machine learning or data mining, e.g. knowledge discovery or pattern finding
-
- G—PHYSICS
- G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
- G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
- G16B40/00—ICT specially adapted for biostatistics; ICT specially adapted for bioinformatics-related machine learning or data mining, e.g. knowledge discovery or pattern finding
- G16B40/10—Signal processing, e.g. from mass spectrometry [MS] or from PCR
-
- G—PHYSICS
- G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
- G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
- G16B40/00—ICT specially adapted for biostatistics; ICT specially adapted for bioinformatics-related machine learning or data mining, e.g. knowledge discovery or pattern finding
- G16B40/20—Supervised data analysis
-
- G—PHYSICS
- G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
- G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
- G16B5/00—ICT specially adapted for modelling or simulations in systems biology, e.g. gene-regulatory networks, protein interaction networks or metabolic networks
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Physics & Mathematics (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Health & Medical Sciences (AREA)
- Medical Informatics (AREA)
- Chemical & Material Sciences (AREA)
- Spectroscopy & Molecular Physics (AREA)
- Biophysics (AREA)
- Biotechnology (AREA)
- Theoretical Computer Science (AREA)
- Evolutionary Biology (AREA)
- Bioinformatics & Computational Biology (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Data Mining & Analysis (AREA)
- Public Health (AREA)
- Immunology (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- Evolutionary Computation (AREA)
- Medicinal Chemistry (AREA)
- Artificial Intelligence (AREA)
- Software Systems (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Computer Vision & Pattern Recognition (AREA)
- Databases & Information Systems (AREA)
- Bioethics (AREA)
- Pharmacology & Pharmacy (AREA)
- Analytical Chemistry (AREA)
- Biochemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Zoology (AREA)
- General Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Microbiology (AREA)
Applications Claiming Priority (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201862783914P | 2018-12-21 | 2018-12-21 | |
US201962826827P | 2019-03-29 | 2019-03-29 | |
US201962855379P | 2019-05-31 | 2019-05-31 | |
US201962891101P | 2019-08-23 | 2019-08-23 | |
PCT/US2019/068084 WO2020132586A1 (en) | 2018-12-21 | 2019-12-20 | Method and systems for prediction of hla class ii-specific epitopes and characterization of cd4+ t cells |
Publications (1)
Publication Number | Publication Date |
---|---|
SG11202106678PA true SG11202106678PA (en) | 2021-07-29 |
Family
ID=71101917
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
SG11202106678PA SG11202106678PA (en) | 2018-12-21 | 2019-12-20 | Method and systems for prediction of hla class ii-specific epitopes and characterization of cd4+ t cells |
Country Status (12)
Country | Link |
---|---|
US (2) | US11183272B2 (en) |
EP (1) | EP3899954A4 (en) |
JP (2) | JP7236543B2 (en) |
KR (2) | KR20240091046A (en) |
CN (1) | CN113474840A (en) |
AU (1) | AU2019404547A1 (en) |
BR (1) | BR112021012278A2 (en) |
CA (1) | CA3124457A1 (en) |
IL (1) | IL284195A (en) |
MX (1) | MX2021007556A (en) |
SG (1) | SG11202106678PA (en) |
WO (1) | WO2020132586A1 (en) |
Families Citing this family (28)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CA3053133A1 (en) * | 2017-02-12 | 2018-08-16 | Neon Therapeutics, Inc. | Hla-based methods and compositions and uses thereof |
US11176429B2 (en) * | 2019-05-13 | 2021-11-16 | International Business Machines Corporation | Counter rare training date for artificial intelligence |
WO2020242765A1 (en) | 2019-05-31 | 2020-12-03 | Rubryc Therapeutics, Inc. | Meso-scale engineered peptides and methods of selecting |
AU2021283380A1 (en) * | 2020-06-03 | 2023-01-05 | Alexis Bio, Inc. | Selection and monitoring methods for xenotransplantation |
WO2021257879A1 (en) * | 2020-06-18 | 2021-12-23 | Personalis Inc. | Machine-learning techniques for predicting surface-presenting peptides |
WO2022043881A1 (en) * | 2020-08-28 | 2022-03-03 | Immunitybio, Inc. | Computerized tool for prediction of proteasomal cleavage |
US11403316B2 (en) | 2020-11-23 | 2022-08-02 | Peptilogics, Inc. | Generating enhanced graphical user interfaces for presentation of anti-infective design spaces for selecting drug candidates |
US20240096443A1 (en) * | 2020-12-01 | 2024-03-21 | Ibio, Inc. | Generalized Scaffolds for Polypeptide Display and Uses Thereof |
WO2022121973A1 (en) * | 2020-12-09 | 2022-06-16 | 江苏恒瑞医药股份有限公司 | Machine learning-based peptide immunogenicity prediction and identification system and method |
EP4315338A1 (en) * | 2021-03-25 | 2024-02-07 | Genentech, Inc. | Using neural networks to predict peptide immunogenicity |
US11512345B1 (en) | 2021-05-07 | 2022-11-29 | Peptilogics, Inc. | Methods and apparatuses for generating peptides by synthesizing a portion of a design space to identify peptides having non-canonical amino acids |
CN113724787B (en) * | 2021-07-28 | 2024-05-03 | 扬州大学 | Protein complex identification method based on core-accessory structure |
CN113807468B (en) * | 2021-10-15 | 2022-05-27 | 南京澄实生物科技有限公司 | HLA antigen presentation prediction method and system based on multi-mode depth coding |
CN113936748B (en) * | 2021-11-17 | 2024-08-20 | 西安电子科技大学 | Molecular recognition feature function prediction method based on ensemble learning |
CN114446385B (en) * | 2022-01-29 | 2024-08-13 | 杭州纽安津生物科技有限公司 | Method and device for acquiring HLA II type molecule and polypeptide affinity prediction model |
WO2023164425A1 (en) * | 2022-02-22 | 2023-08-31 | The Children's Hospital Of Philadelphia | Systems and methods for generating chimeric major histocompatibility complex (mhc) molecules with desired peptide-binding specificities |
AU2023245692A1 (en) * | 2022-03-29 | 2024-10-17 | Ahead Intelligence Ltd. | Methods and devices of processing cytometric data |
WO2023225207A2 (en) * | 2022-05-19 | 2023-11-23 | Biontech Us Inc. | Method and systems for prediction of hla class ii-specific epitopes and characterization of cd4+ t cells |
WO2024015892A1 (en) * | 2022-07-13 | 2024-01-18 | The Broad Institute, Inc. | Hla-ii immunopeptidome methods and systems for antigen discovery |
CN114913939B (en) * | 2022-07-19 | 2022-11-15 | 北京科技大学 | Drug combination design method and device for high-throughput platform and machine learning optimization |
CN115331728B (en) * | 2022-08-12 | 2023-06-30 | 杭州力文所生物科技有限公司 | Stable folding disulfide bond-rich polypeptide design method and electronic equipment thereof |
WO2024036308A1 (en) * | 2022-08-12 | 2024-02-15 | Biontech Us Inc. | Methods and systems for prediction of hla epitopes |
CN115333735B (en) * | 2022-10-11 | 2023-03-14 | 浙江御安信息技术有限公司 | Safe data transmission method |
WO2024115638A1 (en) | 2022-12-01 | 2024-06-06 | Immunewatch Bv | Method to evaluate the conspicuousness of an epitope towards the repertoire of t-cell receptors |
WO2024192143A1 (en) * | 2023-03-13 | 2024-09-19 | Gritstone Bio, Inc. | Epitope prediction via a learned genotype network across class ii mhc alleles |
WO2024194208A1 (en) * | 2023-03-17 | 2024-09-26 | Achilles Therapeutics Uk Limited | Prediction of immunogenicity |
CN116469457B (en) * | 2023-06-14 | 2023-10-13 | 普瑞基准科技(北京)有限公司 | Predictive model training method and device for combining, presenting and immunogenicity of MHC and antigen polypeptide |
CN118248214A (en) * | 2024-02-01 | 2024-06-25 | 南方海洋科学与工程广东省实验室(珠海) | High-confidence intestinal flora single amino acid mutation identification method and application thereof |
Family Cites Families (102)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5833975A (en) | 1989-03-08 | 1998-11-10 | Virogenetics Corporation | Canarypox virus expressing cytokine and/or tumor-associated antigen DNA sequence |
US5766920A (en) | 1982-08-11 | 1998-06-16 | Cellcor, Inc. | Ex vivo activation of immune cells |
US4588585A (en) | 1982-10-19 | 1986-05-13 | Cetus Corporation | Human recombinant cysteine depleted interferon-β muteins |
US4703004A (en) | 1984-01-24 | 1987-10-27 | Immunex Corporation | Synthesis of protein with an identification peptide |
US4751180A (en) | 1985-03-28 | 1988-06-14 | Chiron Corporation | Expression using fused genes providing for protein product |
US4935233A (en) | 1985-12-02 | 1990-06-19 | G. D. Searle And Company | Covalently linked polypeptide cell modulators |
AU7873187A (en) | 1986-08-08 | 1988-02-24 | University Of Minnesota | Method of culturing leukocytes |
US4851341A (en) | 1986-12-19 | 1989-07-25 | Immunex Corporation | Immunoaffinity purification system |
CA1341245C (en) | 1988-01-12 | 2001-06-05 | F. Hoffmann-La Roche Ag | Recombinant vaccinia virus mva |
US5906936A (en) | 1988-05-04 | 1999-05-25 | Yeda Research And Development Co. Ltd. | Endowing lymphocytes with antibody specificity |
US6780407B1 (en) | 1989-03-08 | 2004-08-24 | Aventis Pasteur | Pox virus comprising DNA sequences encoding CEA and B7 antigen |
US5126132A (en) | 1989-08-21 | 1992-06-30 | The United States Of America As Represented By The Department Of Health And Human Services | Tumor infiltrating lymphocytes as a treatment modality for human cancer |
US5728388A (en) | 1989-10-03 | 1998-03-17 | Terman; David S. | Method of cancer treatment |
US6309647B1 (en) | 1999-07-15 | 2001-10-30 | Aventis Pasteur | Poxvirus—canine dispemper virus (CDV) or measles virus recombinants and compositions and methods employing the recombinants |
US6277558B1 (en) | 1990-11-30 | 2001-08-21 | Kansas University Medical Center | α-3 chain type IV collagen polynucleotides |
US6753162B1 (en) | 1991-03-07 | 2004-06-22 | The General Hospital Corporation | Targeted cytolysis of HIV-infected cells by chimeric CD4 receptor-bearing cells |
US5851828A (en) | 1991-03-07 | 1998-12-22 | The General Hospital Corporation | Targeted cytolysis of HIV-infected cells by chimeric CD4 receptor-bearing cells |
US5912170A (en) | 1991-03-07 | 1999-06-15 | The General Hospital Corporation | Redirection of cellular immunity by protein-tyrosine kinase chimeras |
US6004811A (en) | 1991-03-07 | 1999-12-21 | The Massachussetts General Hospital | Redirection of cellular immunity by protein tyrosine kinase chimeras |
US5843728A (en) | 1991-03-07 | 1998-12-01 | The General Hospital Corporation | Redirection of cellular immunity by receptor chimeras |
JP3029135B2 (en) | 1991-04-23 | 2000-04-04 | キヤノン株式会社 | Character processing apparatus and method |
IL104570A0 (en) | 1992-03-18 | 1993-05-13 | Yeda Res & Dev | Chimeric genes and cells transformed therewith |
US8211422B2 (en) | 1992-03-18 | 2012-07-03 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Chimeric receptor genes and cells transformed therewith |
DE4237113B4 (en) | 1992-11-03 | 2006-10-12 | "Iba Gmbh" | Peptides and their fusion proteins, expression vector and method of producing a fusion protein |
US6991797B2 (en) | 1993-07-02 | 2006-01-31 | Statens Serum Institut | M. tuberculosis antigens |
DE69434520T3 (en) | 1993-07-30 | 2009-10-15 | Affymax, Inc., Palo Alto | BIOTINYLATION OF PROTEINS |
AU7478394A (en) | 1993-08-06 | 1995-02-28 | Cytel Corporation | Methods for (ex vivo) therapy using peptide-loaded antigen presenting cells for the activation of ctl |
US5658785A (en) | 1994-06-06 | 1997-08-19 | Children's Hospital, Inc. | Adeno-associated virus materials and methods |
US6924128B2 (en) | 1994-12-06 | 2005-08-02 | Targeted Genetics Corporation | Packaging cell lines for generation of high titers of recombinant AAV vectors |
US5712149A (en) | 1995-02-03 | 1998-01-27 | Cell Genesys, Inc. | Chimeric receptor molecules for delivery of co-stimulatory signals |
US5635363A (en) | 1995-02-28 | 1997-06-03 | The Board Of Trustees Of The Leland Stanford Junior University | Compositions and methods for the detection, quantitation and purification of antigen-specific T cells |
EP0814838B1 (en) | 1995-03-08 | 2003-05-14 | The Scripps Research Institute | Antigen presenting system and activation of t-cells |
US6013516A (en) | 1995-10-06 | 2000-01-11 | The Salk Institute For Biological Studies | Vector and method of use for nucleic acid delivery to non-dividing cells |
DE19781652T1 (en) | 1996-03-13 | 1999-05-12 | Analogic Corp | Self-adjusting ring suppression filter for computed tomography |
US6156567A (en) | 1996-07-03 | 2000-12-05 | Merial | Truncated transcriptionally active cytomegalovirus promoters |
US6090393A (en) | 1996-07-03 | 2000-07-18 | Merial | Recombinant canine adenoviruses, method for making and uses thereof |
US7198784B2 (en) | 1996-10-17 | 2007-04-03 | Oxford Biomedica (Uk) Limited | Retroviral vectors |
CN1195863C (en) | 1996-10-17 | 2005-04-06 | 牛津生物医学(英国)有限公司 | Retroviral vectors |
US7255862B1 (en) | 1996-11-14 | 2007-08-14 | Connaught Technology Corporation | ALVAC/FIV constructs |
US6194207B1 (en) | 1997-01-31 | 2001-02-27 | Hemosol Inc. | Methods for the selective expansion of lymphocytes by in vitro cultivation |
AU745049B2 (en) | 1997-03-11 | 2002-03-07 | Regents Of The University Of Minnesota | DNA-based transposon system for the introduction of nucleic acid into DNA of a cell |
CA2303768C (en) | 1997-09-19 | 2009-11-24 | The Trustees Of The University Of Pennsylvania | Methods and vector constructs useful for production of recombinant aav |
AU9397098A (en) | 1997-09-19 | 1999-04-12 | Trustees Of The University Of Pennsylvania, The | Methods and cell line useful for production of recombinant adeno-associated viruses |
GB9720465D0 (en) | 1997-09-25 | 1997-11-26 | Oxford Biomedica Ltd | Dual-virus vectors |
US6346415B1 (en) | 1997-10-21 | 2002-02-12 | Targeted Genetics Corporation | Transcriptionally-activated AAV inverted terminal repeats (ITRS) for use with recombinant AAV vectors |
US5994136A (en) | 1997-12-12 | 1999-11-30 | Cell Genesys, Inc. | Method and means for producing high titer, safe, recombinant lentivirus vectors |
US6953690B1 (en) | 1998-03-20 | 2005-10-11 | The Trustees Of The University Of Pennsylvania | Compositions and methods for helper-free production of recombinant adeno-associated viruses |
ES2340230T3 (en) | 1998-11-10 | 2010-05-31 | University Of North Carolina At Chapel Hill | VIRIC VECTORS AND THEIR PREPARATION AND ADMINISTRATION PROCEDURES. |
US7160682B2 (en) | 1998-11-13 | 2007-01-09 | Regents Of The University Of Minnesota | Nucleic acid transfer vector for the introduction of nucleic acid into the DNA of a cell |
US6258595B1 (en) | 1999-03-18 | 2001-07-10 | The Trustees Of The University Of Pennsylvania | Compositions and methods for helper-free production of recombinant adeno-associated viruses |
US6893865B1 (en) | 1999-04-28 | 2005-05-17 | Targeted Genetics Corporation | Methods, compositions, and cells for encapsidating recombinant vectors in AAV particles |
US6913922B1 (en) | 1999-05-18 | 2005-07-05 | Crucell Holland B.V. | Serotype of adenovirus and uses thereof |
US6492169B1 (en) | 1999-05-18 | 2002-12-10 | Crucell Holland, B.V. | Complementing cell lines |
US6793926B1 (en) | 1999-05-27 | 2004-09-21 | Genovo, Inc. | Methods for production of a recombinant adeno-associated virus |
DK1180159T3 (en) | 1999-05-28 | 2008-11-17 | Targeted Genetics Corp | Methods and Compositions to Lower the Level of Tumor Necrosis Factor (TNF) in TNF-Associated Disorders |
US6955808B2 (en) | 1999-09-24 | 2005-10-18 | Uab Research Foundation | Capsid-modified recombinant adenovirus and methods of use |
US7115391B1 (en) | 1999-10-01 | 2006-10-03 | Genovo, Inc. | Production of recombinant AAV using adenovirus comprising AAV rep/cap genes |
AU785493B2 (en) | 2000-03-27 | 2008-01-03 | Technion Research & Development Foundation Ltd. | Single chain class I major histo-compatibility complexes, constructs encoding same and methods of generating same |
GB0024550D0 (en) | 2000-10-06 | 2000-11-22 | Oxford Biomedica Ltd | |
CA2432172C (en) | 2000-12-15 | 2009-01-20 | Balwinder Singh Aulakh | An in vivo method for producing female offsprings in mammals |
GB0202334D0 (en) | 2001-04-05 | 2002-03-20 | Nextgen Sciences Ltd | Protein analysis |
CA2457652C (en) | 2001-08-31 | 2012-08-07 | Avidex Limited | Soluble t cell receptor |
WO2003089618A2 (en) | 2002-04-22 | 2003-10-30 | Regents Of The University Of Minnesota | Transposon system and methods of use |
JP4436319B2 (en) | 2002-10-09 | 2010-03-24 | メディジーン リミテッド | Single-chain recombinant T cell receptor |
EP2048159B1 (en) | 2002-11-09 | 2014-01-01 | Immunocore Ltd. | T cell receptor display |
GB0304068D0 (en) | 2003-02-22 | 2003-03-26 | Avidex Ltd | Substances |
US7985739B2 (en) | 2003-06-04 | 2011-07-26 | The Board Of Trustees Of The Leland Stanford Junior University | Enhanced sleeping beauty transposon system and methods for using the same |
NZ549731A (en) * | 2004-03-01 | 2009-11-27 | Peptimmune Inc | Methods and compositions for treatment of autoimmune diseases |
AR048035A1 (en) | 2004-03-11 | 2006-03-22 | Fresenius Kabi De Gmbh | CONJUGADOS DE ALMIDON DE HIDROXIALQUILO AND A PROTEIN, PREPARED BY REDUCING AMINATION |
NZ550810A (en) | 2004-05-19 | 2009-05-31 | Immunocore Ltd | High affinity NY-ESO T cell receptor |
AU2005246073B2 (en) | 2004-05-19 | 2010-10-28 | Adaptimmune Limited | Method of improving T cell receptors |
WO2006000830A2 (en) | 2004-06-29 | 2006-01-05 | Avidex Ltd | Cells expressing a modified t cell receptor |
FR2881746B1 (en) | 2005-02-07 | 2007-04-13 | Centre Nat Rech Scient | CD4 + EPITOPES OF TYTE I AND II LATENCY ANTIGENS OF THE EPSTEIN-BARR VIRUS FIT TO BE RECOGNIZED BY THE MAJORITY OF INDIVIDUALS OF THE CAUCASIAN POPULATION AND THEIR APPLICATIONS |
EP1858332A4 (en) | 2005-02-16 | 2011-06-22 | Lentigen Corp | Lentiviral vectors and their use |
AR052741A1 (en) | 2005-04-08 | 2007-03-28 | Noxxon Pharma Ag | NUCLEIC ACIDS FROM UNION TO GHRELIN |
WO2006125962A2 (en) | 2005-05-25 | 2006-11-30 | Medigene Limited | T cell receptors which specifically bind to vygfvracl-hla-a24 |
GB2442048B (en) | 2006-07-25 | 2009-09-30 | Proimmune Ltd | Biotinylated MHC complexes and their uses |
US8088379B2 (en) | 2006-09-26 | 2012-01-03 | The United States Of America As Represented By The Department Of Health And Human Services | Modified T cell receptors and related materials and methods |
EP2087000A2 (en) | 2006-09-29 | 2009-08-12 | Immunocore Ltd. | T cell therapies |
CA2776241A1 (en) | 2009-10-30 | 2011-05-05 | Novozymes Biopharma Dk A/S | Albumin variants |
WO2011091319A2 (en) | 2010-01-22 | 2011-07-28 | Baylor Research Institute | Dendritic cell vaccines |
EP2575894B1 (en) | 2010-05-28 | 2015-02-25 | Oxford Biomedica (UK) Ltd | Delivery of lentiviral vectors to the brain |
SG190997A1 (en) | 2010-12-09 | 2013-07-31 | Univ Pennsylvania | Use of chimeric antigen receptor-modified t cells to treat cancer |
US8999937B2 (en) | 2011-02-28 | 2015-04-07 | Indiana University Research And Technology Corporation | Glucocorticoid induced leucine zipper mimetics as therapeutic agents in multiple sclerosis |
US20130071414A1 (en) | 2011-04-27 | 2013-03-21 | Gianpietro Dotti | Engineered cd19-specific t lymphocytes that coexpress il-15 and an inducible caspase-9 based suicide gene for the treatment of b-cell malignancies |
AU2012257377B2 (en) | 2011-05-17 | 2017-09-07 | Hadasit Medical Research Services And Development Ltd. | Allogeneic tumor cell vaccination |
US20120295960A1 (en) | 2011-05-20 | 2012-11-22 | Oxford Biomedica (Uk) Ltd. | Treatment regimen for parkinson's disease |
WO2012159643A1 (en) | 2011-05-24 | 2012-11-29 | Biontech Ag | Individualized vaccines for cancer |
DK2714071T3 (en) * | 2011-05-24 | 2019-09-16 | Biontech Rna Pharmaceuticals Gmbh | INDIVIDUALIZED VACCINES AGAINST CANCER |
PT2755997T (en) | 2011-09-15 | 2018-10-30 | Us Health | T cell receptors recognizing hla-a1- or hla-cw7-restricted mage |
US9751928B2 (en) | 2012-05-03 | 2017-09-05 | Fred Hutchinson Cancer Research Center | Enhanced affinity T cell receptors and methods for making the same |
RU2020108070A (en) | 2012-07-27 | 2020-03-16 | Дзе Борд Оф Трастиз Оф Дзе Юниверсити Оф Иллинойс | CONSTRUCTION OF T-CELL RECEPTORS |
GB2508414A (en) | 2012-11-30 | 2014-06-04 | Max Delbrueck Centrum | Tumour specific T cell receptors (TCRs) |
RS60759B1 (en) | 2013-02-26 | 2020-10-30 | Memorial Sloan Kettering Cancer Center | Compositions and methods for immunotherapy |
US11725237B2 (en) | 2013-12-05 | 2023-08-15 | The Broad Institute Inc. | Polymorphic gene typing and somatic change detection using sequencing data |
WO2016128060A1 (en) | 2015-02-12 | 2016-08-18 | Biontech Ag | Predicting t cell epitopes useful for vaccination |
CN108601731A (en) * | 2015-12-16 | 2018-09-28 | 磨石肿瘤生物技术公司 | Discriminating, manufacture and the use of neoantigen |
WO2017184590A1 (en) * | 2016-04-18 | 2017-10-26 | The Broad Institute Inc. | Improved hla epitope prediction |
US20200182884A1 (en) | 2016-06-27 | 2020-06-11 | Juno Therapeutics, Inc. | Method of identifying peptide epitopes, molecules that bind such epitopes and related uses |
CA3053133A1 (en) * | 2017-02-12 | 2018-08-16 | Neon Therapeutics, Inc. | Hla-based methods and compositions and uses thereof |
US11485784B2 (en) | 2017-03-31 | 2022-11-01 | Act Genomics (Ip) Co., Ltd. | Ranking system for immunogenic cancer-specific epitopes |
CA3101310A1 (en) * | 2018-03-12 | 2019-09-19 | The Children's Hospital Of Philadelphia | Methods and compositions for use of tumor self-antigens in adoptive immunotherapy |
-
2019
- 2019-12-20 BR BR112021012278A patent/BR112021012278A2/en unknown
- 2019-12-20 JP JP2021536205A patent/JP7236543B2/en active Active
- 2019-12-20 WO PCT/US2019/068084 patent/WO2020132586A1/en unknown
- 2019-12-20 CN CN201980092864.1A patent/CN113474840A/en active Pending
- 2019-12-20 MX MX2021007556A patent/MX2021007556A/en unknown
- 2019-12-20 EP EP19898619.2A patent/EP3899954A4/en active Pending
- 2019-12-20 KR KR1020247017602A patent/KR20240091046A/en active Search and Examination
- 2019-12-20 SG SG11202106678PA patent/SG11202106678PA/en unknown
- 2019-12-20 CA CA3124457A patent/CA3124457A1/en active Pending
- 2019-12-20 KR KR1020217022939A patent/KR102670790B1/en active IP Right Grant
- 2019-12-20 AU AU2019404547A patent/AU2019404547A1/en active Pending
-
2020
- 2020-03-19 US US16/824,331 patent/US11183272B2/en active Active
-
2021
- 2021-06-20 IL IL284195A patent/IL284195A/en unknown
- 2021-10-06 US US17/495,571 patent/US20220199198A1/en active Pending
-
2023
- 2023-02-27 JP JP2023028268A patent/JP7531009B2/en active Active
Also Published As
Publication number | Publication date |
---|---|
CN113474840A (en) | 2021-10-01 |
JP2022518355A (en) | 2022-03-15 |
WO2020132586A1 (en) | 2020-06-25 |
MX2021007556A (en) | 2021-09-10 |
JP7236543B2 (en) | 2023-03-09 |
JP2023071806A (en) | 2023-05-23 |
US20220199198A1 (en) | 2022-06-23 |
JP7531009B2 (en) | 2024-08-08 |
KR20240091046A (en) | 2024-06-21 |
CA3124457A1 (en) | 2020-06-25 |
KR102670790B1 (en) | 2024-05-29 |
US11183272B2 (en) | 2021-11-23 |
EP3899954A1 (en) | 2021-10-27 |
EP3899954A4 (en) | 2022-09-14 |
IL284195A (en) | 2021-08-31 |
KR20210130705A (en) | 2021-11-01 |
US20200279616A1 (en) | 2020-09-03 |
AU2019404547A1 (en) | 2021-07-22 |
BR112021012278A2 (en) | 2021-12-14 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
IL284195A (en) | Method and systems for prediction of hla class ii-specific epitopes and characterization of cd4+ t cells | |
IL282735A (en) | Compositions and methods for t cell engineering | |
MX2019000180A (en) | T cell compositions for immunotherapy. | |
IL276131A (en) | Methods of use for car t cells | |
EP3476934A4 (en) | Method for producing cd4/cd8 double-positive t cells | |
EP3273523A4 (en) | Apparatus and method for estimating degree of aging of secondary battery | |
EP3252918A4 (en) | Apparatus and method for adjusting charging condition of secondary battery | |
EP3623829A4 (en) | Apparatus for estimating state-of-charge of secondary battery and method thereof | |
EP3449584A4 (en) | Intermediary satellite network for cross-strapping and local network decongestion | |
MX2016012713A (en) | Claudin-6-specific immunoreceptors and t cell epitopes. | |
EP3694408A4 (en) | Method for neuromechanical and neuroelectromagnetic mitigation of limb pathology | |
EP3273710A4 (en) | Method and device for transmitting and receiving list of cells providing scptm service | |
EP3423056A4 (en) | Methods for controlled proliferation of stem cells / generating inner ear hair cells using gsk-3-alpha inhibitors | |
HK1224340A1 (en) | Method for isolating and proliferating self-tumor antigen-specific cd8 t cells cd8 t | |
IL282901A (en) | Methods for isolating and expanding cells | |
EP3732835A4 (en) | System and method for providing satellite gtp acceleration for secure cellular backhaul over satellite | |
IL289995A (en) | Method of obtaining mitochondria from cells and mitochondria obtained thereby | |
EP3531149A4 (en) | Apparatus and method for estimating capacity retention ratio of secondary battery | |
HUE066395T2 (en) | System and method for inspecting welding of secondary battery | |
TWI562661B (en) | Cell and method and system for bandwidth management of backhaul network of cell | |
SG11202108613RA (en) | Compositions and methods for identification of antigen specific t cells | |
IL277394A (en) | System and method for generation of gases | |
EP3438684A4 (en) | Device for estimating degradation of secondary cell, and method for estimating degradation of secondary cell | |
IL282110A (en) | Method for activation/proliferation of t cells | |
IL282876A (en) | Methods for isolating and expanding cells |